Advertisement

U.S. Markets closed

S&P Futures
5,912.00
+6.00(+0.10%)
Dow Futures
43,572.00
+54.00(+0.12%)
Nasdaq Futures
20,505.75
+22.25(+0.11%)
Russell 2000 Futures
2,296.60
+5.40(+0.24%)
Crude Oil
69.52
+0.30(+0.43%)
Gold
2,740.40
+10.40(+0.38%)

Innovent Biologics Inc. (IVBIY)

OTC Markets OTCPK - OTC Markets OTCPK Delayed Price. Currency in USD

22.00

0.00

(0.00%)

At close: 04:00PM EDT

Loading interactive chart...

Clinical Trials Arena
Innovent’s trial of picankibart for ulcerative colitis meets primary endpoint
The primary endpoint was clinical remission at week 12, with secondary endpoints of clinical response and endoscopic remission.
PR Newswire
Innovent Announces Phase 2 Clinical Study of Picankibart (IBI112) in Chinese Patients with Ulcerative Colitis Met Primary Endpoint
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major diseases, announces that primary endpoint of 12-week induction period was met in a multicenter, randomized, double-blind, placebo-controlled phase 2 clinical study (ClinicalTrials.gov, NCT05377580) of picankibart (R&D code: IBI112), a